恩华药业公告，公司拟出资350万美元购买三晟医药的Pre-A轮优先股1250万股，交易完成后公司将持有三晟医药10.448%的股权。三晟医药是一家专注于发现和开发治疗中枢神经系统疾病的创新药物的生物科技公司。此次投资旨在加快创新药物的研发及引进工作，提升公司药物研发效率及市场竞争力，获取新的利润增长点。交易完成后，三晟医药将成为公司的参股公司。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：小浪快报

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.